Japan’s Eisai Co. announced Tuesday that its potential treatment appears to slow Alzheimer’s. The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27 percent compared to a placebo or fake drug after 18 months of the infused treatment. The global study involved nearly 1,800 people with early-stage Alzheimer’s patients who were monitored using a scale that measures mental decline and their ability to do daily activities like getting dressed or feeding oneself. The company is seeking an accelerated approval from the FDA, and the agency is expected to decide by early next year. Eisai and Biogen will co-promote the drug. Read more here.
NCPA
